Preliminary data from clinical trials in solid tumors and HL indicate that patients with PD-L1+ tumor cells were those who benefitted most from PD-1/PD-L1 immune checkpoint blockade treatments [15, 93–94]. This evidence concerns the gene PDCD1 and neoplasm.